Cardiac Science To Present Important New Findings In Assessing Risk Of Cardiovascular Death

BOTHELL, Wash., March 7 /PRNewswire-FirstCall/ -- Cardiac Science Corporation , a global leader in advanced cardiac monitoring and defibrillation products sold under the trusted Quinton(R), Powerheart(R) and Burdick(R) brands, today announced that it will present groundbreaking new research for assessing a patient's risk of cardiovascular death at the American College of Cardiology's 55th Annual Scientific Session in Atlanta, Georgia being held on March 11-14, 2006.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050913/SFTU139LOGO )

The research, conducted in collaboration with Stanford University Medical Center/VA Palo Alto Health Care System, will be presented at Poster Session 1017 titled "New Advances in Exercise Physiology and Testing," on Tuesday, March 14 at 12:30 p.m. in the Georgia World Congress Center (Hall B1).

"Cardiac Science Corporation is committed to supporting innovative research in cardiac diagnosis and care," said John Hinson, president and CEO of Cardiac Science Corporation. "We are excited to advance the cardiology industry's breadth of knowledge in effectively identifying patients at risk of cardiovascular death -- the number one cause of death in the United States."

The research involves new methods for analyzing cardiac stress testing data. A market leader under its Quinton(R) and Burdick(R) brands, Cardiac Science has more than a half-century of history and experience delivering high-quality cardiac stress testing products.

The abstract, titled "Can Exercise Induced Heart Rate Variability Spectral Slopes Provide Insights Into Autonomic Activity and Prognosis?" will be presented by Cardiac Science Vice President of Research, Dave Hadley, PhD.

Dr. Victor Froelicher, Professor of Medicine at the Stanford University School of Medicine and Director of ECG and Exercise Laboratories at the Palo Alto VA Health Care System, collaborated with Dr. Hadley in conducting the research.

About Cardiac Science Corporation

Cardiac Science Corporation develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators, electrocardiographs, stress test systems, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, patient monitor-defibrillators and cardiology data management systems. Cardiac Science Corporation also sells a variety of related products and consumables, and provides a comprehensive portfolio of training, maintenance and support services.

The company is the successor to various entities that have owned and operated cardiology-related businesses, which sold products under the trusted brand names Burdick(R), Powerheart(R), and Quinton(R). Cardiac Science Corporation is headquartered in Bothell, WA, and also has operations in Lake Forest, California, Deerfield, Wisconsin, Shanghai, China, Copenhagen, Denmark and Manchester, United Kingdom.

Forward Looking Statements

This press release contains forward-looking statements. The words "believe," "expect," "intend," anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward-looking statements in this press release include those that infer or imply that we will be able to successfully commercialize applications incorporating new diagnostic cardiology techniques. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks are more fully described in the registration statement on Form S-4/A that was filed by Cardiac Science Corporation under the name CSQ Holding Company on July 28, 2005, under the caption "Risk Factors," and in the Annual Reports of Quinton Cardiology Systems, Inc. and Cardiac Science, Inc. on Form 10-K for the year ended December 31, 2004, under the captions "Certain Factors that May Affect Future Results," in Cardiac Science Corporation's Quarterly Report on Form 10-Q for the quarter ended September 30, 2005 under the caption "Certain Factors that May Affect Future Results" and in other documents, we file with the Securities and Exchange Commission. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.

Media Contacts Mike Matysik Cardiac Science Corp. Sr. Vice President and CFO (425) 402-2009 Traci Paulk The Fearey Group for Cardiac Science Corp. (206) 343-1543

CONTACT: Mike Matysik, Sr. Vice President and CFO of Cardiac ScienceCorp., +1-425-402-2009; or Traci Paulk of The Fearey Group,+1-206-343-1543, for Cardiac Science Corp.

Web site: http://www.cardiacscience.com/